en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
Press Releases
2026
2025
2024
2023
2022
2021
2020
All
Regulatory
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oct 31, 2023
2023
Press Release Regulatory
Nomination Committee for Elicera therapeutics appointed
Regulatory
Read more
Sep 8, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Read more
Aug 29, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Regulatory
Read more
Aug 10, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Read more
Jul 11, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
Read more
May 16, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023
Regulatory
Read more
Apr 28, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)
Read more
Apr 17, 2023
2023
Press Release Regulatory
Elicera Therapeutics publishes the annual report for 2022
Regulatory
Read more
Mar 6, 2023
2023
Press Release Non-regulatory
Erik Penser Bank initiates coverage on Elicera Therapeutics
Read more
Mar 1, 2023
2023
Press Release Regulatory
Elicera Therapeutics hires Erik Penser Bank as market maker
Regulatory
Read more
Feb 17, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Regulatory
Read more
Feb 7, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Read more
Jan 26, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma
Read more
Jan 23, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3
Read more
Dec 7, 2022
2022
Press Release Regulatory
Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston
Regulatory
Read more
Nov 18, 2022
2022
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022
Regulatory
Read more
Nov 16, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research
Read more
Nov 3, 2022
2022
Press Release Regulatory
Nomination Committee for Elicera Therapeutics appointed
Regulatory
Read more
Oct 18, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution
Read more
Oct 12, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy
Read more
Previous
+ Load more
4 / 6
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept